#Liechtenstein #RefluxStop #Implantica AG #Ruggell #MedTech Innovation

Highlights of Implantica AG's Annual General Meeting

On May 15, 2025, the Annual General Meeting (AGM) of Implantica AG took place in Ruggell, Liechtenstein. This annual event is crucial for shareholders to discuss the company’s progress, governance, and future direction. At this year’s meeting, several important resolutions were adopted, setting the tone for Implantica’s operational future.

Key Resolutions Adopted

Financial Overview

The AGM approved the annual report for 2024, which included both the statutory and consolidated financial statements. One of the significant highlights was the acknowledgment of a net loss for the financial year 2024, resulting in the decision to carry forward the loss and pay no dividends to shareholders. This choice reflects the company’s commitment to re-invest in future growth opportunities rather than distribute earnings at this stage.

Board of Directors Discharge

A critical part of the AGM involved discharging the members of the board of directors, as well as the executive management and auditors, from liability for their services in the financial year 2024. This step demonstrates shareholder confidence in the management and the oversight provided by the board.

Executive Compensation

The shareholders also approved the total remuneration packages for the board of directors and executive management, amounting to TEUR 106 and TEUR 821, respectively. This total includes fixed compensation, pension contributions, and incentive plans, reflecting the importance of aligning management interests with long-term shareholder value.

Board Re-Elections

The AGM resolved to re-elect key board members, including Liselott Kilaas, who will continue serving as the chairman, and Johan Bojs, re-elected as vice-chairman. Additionally, the roles within the nomination and remuneration committee were confirmed with Tomas Puusepp joining as a member. Such decisions ensure stability and continuity in leadership, which is vital for strategic development.

Changes to Articles of Association

Another significant resolution included amendments to the Articles of Association. The board is now authorized to issue new shares with or without deviations from shareholders' preferential rights. This flexibility in capital management will enable Implantica to adapt more responsively to market opportunities and bolster its financial flexibility for future growth initiatives.

Outlook on Implantica’s Future

Implantica is recognized for its innovative contributions to the medtech field, particularly with its leading product, RefluxStop™, a cutting-edge implant aimed at preventing gastroesophageal reflux. The company's strategy also emphasizes the integration of eHealth technologies designed to monitor health parameters remotely, offering patients a seamless connection to healthcare providers. This focus on innovation not only positions Implantica as a leader in medtech but also aims to redefine standards in patient care.

Going forward, shareholders and industry observers are eager to see how these resolutions will empower Implantica to leverage its technological advancements while addressing the challenges posed by the competitive healthcare landscape. The upcoming year will be pivotal in solidifying its market position and driving shareholder value, as the company navigates growth driven by innovative solutions in healthcare.

For those interested in further details from the AGM, the full minutes and resolutions are available on the company's official website, ensuring transparency and accessibility to stakeholders.

Conclusion

Implantica AG's AGM sheds light on the company's resilient strategy amidst financial challenges, focusing on future growth fueled by innovation in medical technology. Stakeholder support through the decisions made at the AGM will be instrumental as Implantica moves forward with its ambitious goals in the healthcare arena.